Monte Rosa Therapeutics, Inc. Operating Leases, Future Minimum Payments, Remainder of Fiscal Year
Monte Rosa Therapeutics, Inc. (GLUE) had Operating Leases, Future Minimum Payments, Remainder of Fiscal Year of $500.00 thousand as of 2022-03-31, per its 10-Q filed 2022-05-11.
Discontinued › Notes › Leases
us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear · last filed 2023-03-16
- 2022-03-31: Operating Leases, Future Minimum Payments, Remainder of Fiscal Year $500.00K.
- 2021-12-31: Operating Leases, Future Minimum Payments, Remainder of Fiscal Year $3.16M.
| Period end | Operating Leases, Future Minimum Payments, Remainder of Fiscal Year |
|---|---|
| 2022-03-31 | $500.00K 10-Q · filed 2022-05-11 |
| 2021-12-31 | $3.16M 10-K · filed 2023-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |